Thoroughbred Financial Services LLC lowered its stake in Viking Therapeutics, Inc. (NASDAQ:VKTX - Free Report) by 71.6% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 6,373 shares of the biotechnology company's stock after selling 16,051 shares during the period. Thoroughbred Financial Services LLC's holdings in Viking Therapeutics were worth $256,000 at the end of the most recent quarter.
Several other institutional investors also recently modified their holdings of the stock. Blue Trust Inc. raised its position in shares of Viking Therapeutics by 75.9% during the fourth quarter. Blue Trust Inc. now owns 716 shares of the biotechnology company's stock worth $29,000 after acquiring an additional 309 shares during the last quarter. YANKCOM Partnership bought a new stake in Viking Therapeutics in the fourth quarter worth approximately $33,000. CIBC Private Wealth Group LLC lifted its stake in Viking Therapeutics by 170.2% in the fourth quarter. CIBC Private Wealth Group LLC now owns 1,351 shares of the biotechnology company's stock valued at $55,000 after buying an additional 851 shares during the period. S.A. Mason LLC lifted its position in shares of Viking Therapeutics by 20.0% during the 4th quarter. S.A. Mason LLC now owns 1,800 shares of the biotechnology company's stock valued at $72,000 after acquiring an additional 300 shares during the period. Finally, Wolff Wiese Magana LLC bought a new stake in Viking Therapeutics in the fourth quarter valued at $75,000. 76.03% of the stock is currently owned by institutional investors and hedge funds.
Viking Therapeutics Stock Performance
Shares of NASDAQ VKTX traded down $2.23 during midday trading on Thursday, reaching $20.87. The stock had a trading volume of 1,744,902 shares, compared to its average volume of 3,963,639. The company has a market capitalization of $2.34 billion, a price-to-earnings ratio of -20.81 and a beta of 0.84. Viking Therapeutics, Inc. has a 12-month low of $18.92 and a 12-month high of $81.86. The stock has a 50-day moving average of $28.11 and a 200-day moving average of $43.77.
Viking Therapeutics (NASDAQ:VKTX - Get Free Report) last issued its earnings results on Wednesday, February 5th. The biotechnology company reported ($0.32) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.27) by ($0.05). During the same period in the previous year, the company earned ($0.25) earnings per share. As a group, analysts forecast that Viking Therapeutics, Inc. will post -1.56 EPS for the current fiscal year.
Wall Street Analysts Forecast Growth
A number of research analysts have weighed in on the stock. Raymond James raised their price objective on shares of Viking Therapeutics from $122.00 to $125.00 and gave the company a "strong-buy" rating in a research note on Thursday, February 6th. The Goldman Sachs Group initiated coverage on Viking Therapeutics in a research note on Tuesday. They issued a "neutral" rating and a $30.00 price objective for the company. B. Riley reiterated a "buy" rating and set a $96.00 price target (down previously from $109.00) on shares of Viking Therapeutics in a report on Friday, February 7th. Citigroup started coverage on shares of Viking Therapeutics in a report on Friday, February 7th. They set a "neutral" rating and a $38.00 price objective on the stock. Finally, HC Wainwright reissued a "buy" rating and set a $102.00 price target on shares of Viking Therapeutics in a research report on Wednesday, March 26th. One analyst has rated the stock with a sell rating, two have assigned a hold rating, ten have issued a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $89.75.
Read Our Latest Research Report on VKTX
Insider Transactions at Viking Therapeutics
In related news, Director Sarah Kathryn Rouan bought 1,240 shares of Viking Therapeutics stock in a transaction dated Monday, March 31st. The shares were acquired at an average cost of $24.15 per share, with a total value of $29,946.00. Following the completion of the transaction, the director now owns 1,240 shares in the company, valued at $29,946. The trade was a ∞ increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Insiders own 4.70% of the company's stock.
About Viking Therapeutics
(
Free Report)
Viking Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD.
Featured Stories
Before you consider Viking Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Viking Therapeutics wasn't on the list.
While Viking Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Learn how options trading can help you navigate market volatility, manage risk, and maximize returns with MarketBeat's "Unlock the Potential in Options Trading." Click the link below to have this special report delivered to your inbox.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
